Hormetic modulation of hepatic insulin sensitivity by advanced glycation end products

Mol Cell Endocrinol. 2017 May 15:447:116-124. doi: 10.1016/j.mce.2017.02.035. Epub 2017 Feb 24.

Abstract

Because of the paucity of information regarding metabolic effects of advanced glycation end products (AGEs) on liver, we evaluated effects of AGEs chronic administration in (1) insulin sensitivity; (2) hepatic expression of genes involved in AGEs, glucose and fat metabolism, oxidative stress and inflammation and; (3) hepatic morphology and glycogen content. Rats received intraperitoneally albumin modified (AlbAGE) or not by advanced glycation for 12 weeks. AlbAGE induced whole-body insulin resistance concomitantly with increased hepatic insulin sensitivity, evidenced by activation of AKT, inactivation of GSK3, increased hepatic glycogen content, and decreased expression of gluconeogenesis genes. Additionally there was reduction in hepatic fat content, in expression of lipogenic, pro-inflamatory and pro-oxidative genes and increase in reactive oxygen species and in nuclear expression of NRF2, a transcription factor essential to cytoprotective response. Although considered toxic, AGEs become protective when administered chronically, stimulating AKT signaling, which is involved in cellular defense and insulin sensitivity.

Keywords: AKT; GSK3; Liver; NRF2; RAGE.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Albumins / pharmacology
  • Animals
  • Cell Nucleus / drug effects
  • Cell Nucleus / metabolism
  • Gene Expression Regulation / drug effects
  • Gluconeogenesis / drug effects
  • Gluconeogenesis / genetics
  • Glycation End Products, Advanced / administration & dosage
  • Glycation End Products, Advanced / pharmacology*
  • Glycogen / metabolism
  • Glycogen Synthase Kinase 3 beta / metabolism
  • HMGB1 Protein / metabolism
  • Hormesis / drug effects*
  • Inflammation Mediators / metabolism
  • Injections, Intraperitoneal
  • Insulin Resistance*
  • Lipogenesis / drug effects
  • Lipogenesis / genetics
  • Liver / drug effects
  • Liver / metabolism*
  • Male
  • Models, Biological
  • NF-E2-Related Factor 2 / metabolism
  • Oxidation-Reduction
  • Proto-Oncogene Proteins c-akt / metabolism
  • Rats, Wistar
  • Reactive Oxygen Species / metabolism
  • Sterol Regulatory Element Binding Protein 1 / metabolism

Substances

  • Albumins
  • Glycation End Products, Advanced
  • HMGB1 Protein
  • Inflammation Mediators
  • NF-E2-Related Factor 2
  • Nfe2l2 protein, rat
  • Reactive Oxygen Species
  • Sterol Regulatory Element Binding Protein 1
  • Glycogen
  • Glycogen Synthase Kinase 3 beta
  • Proto-Oncogene Proteins c-akt